PDGFRB and idiopathic pulmonary fibrosis: The angiokinase inhibitor nintedanib which targets VEGFR, PDGFR, and FGFR is approved for the treatment of non-small-cell lung cancer, idiopathic pulmonary fibrosis, and other lung diseases by the FDA and EMA was identified as a novel KIT D816V inhibitor using this model [81].